Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Data
Biotech
HMNC recalibrates precision depression push after phase 2b miss
The ex-Sanofi molecule failed to move the needle in the primary endpoint population but the results in other patients convinced HMNC to push ahead.
Nick Paul Taylor
Aug 5, 2025 10:38am
Vertex drops asset in acute pain after phase 2 fail
Aug 4, 2025 5:34pm
Praxis' drug reduces seizures but sees 23% discontinuation rate
Aug 4, 2025 10:22am
Spine BioPharma misses primary endpoint in back pain phase 3
Aug 1, 2025 10:24am
4DMT climbs as gene therapy patients keep jettisoning jabs
Aug 1, 2025 5:35am
Instil's licensed PD-L1xVEGF bispecific shows promise in China
Jul 31, 2025 2:10pm
